CD8A and non-small cell lung carcinoma: Studies have found that number of effector CD8+ T cells (CCR7−CD45RA−) decreased (Jenkins et al., 2018), whereas number of exhausted tumor-reactive CD8+ T cells (TIGIT + PD-1+) increased in HPD patients with NSCLC (Huang A. C. et al., 2017).